The University of Copenhagen proudly announces Mitra Bio as a Tier 3 Sponsor for the upcoming 12th Aging Research & Drug Discovery Meeting (ARDD 2025), the premier global conference dedicated to biopharmaceutical aging research. This influential event is scheduled to take place from August 25 to August 29, 2025, at the Ceremonial Hall of the University of Copenhagen and will also be accessible online to accommodate the global community. ARDD has cemented its reputation as the largest and most comprehensive forum integrating cutting-edge longevity science with real-world therapeutic applications, drawing a diverse group of stakeholders from academia, industry, and healthcare sectors.
ARDD 2025 positions itself at the confluence of pioneering longevity science and practical impact on human healthspan, embodying the vision of Mitra Bio’s CEO, Dr. Shakiba Kaveh. Mitra Bio has devoted the past five years to advancing the field of skin aging through innovative, non-invasive epigenetic testing methodologies. Their proprietary tape-strip sampling combined with next-generation sequencing revolutionizes traditional biopsy approaches, enabling rapid, painless, and high-resolution epigenetic profiling. This advancement holds exceptional promise for dermatological applications, medical devices, and pharmaceutical research, offering a transformative tool for understanding the molecular underpinnings of skin aging and translating insights into clinically relevant interventions.
ARDD has experienced exponential growth, establishing itself as an exclusive nexus where leading scientists, biotech innovators, venture capitalists, and pharmaceutical executives converge. The conference fosters robust scientific exchange, collaborative partnerships, and exposure to groundbreaking research innovations that are redefining aging as a modifiable biological process. Each year, the gathering spotlights emergent themes from molecular gerontology, cellular senescence, regenerative medicine, to AI-driven drug discovery, reflecting the escalating interdisciplinarity in longevity sciences.
The excitement for ARDD 2025 is further amplified by the participation of Nobel Laureates Professor Morten Meldal and Professor Michael Levitt. Their groundbreaking contributions to molecular design and protein modelling have catalyzed drug discovery and computational biology. According to Professor Morten Scheibye-Knudsen from the University of Copenhagen, their presence will provide invaluable insights and enrich the scientific dialogue at ARDD. The convergence of Nobel-caliber intellects with leading industry practitioners underscores the conference’s unparalleled prominence and ambition.
Professor Daniela Bakula echoes the anticipation surrounding these illustrious guests, emphasizing that their seminal work has reshaped contemporary drug discovery paradigms. Their engagement promises to elevate the conference discourse, inspiring innovative approaches in aging research and pharmaceutical development. These interactions between Nobel laureates, academic leaders, and industry pioneers typify ARDD’s commitment to fostering a vibrant ecosystem dedicated to longevity biotechnology.
Over the past twelve years, ARDD has evolved into the quintessential platform promoting cross-sectoral dialogue among academia, pharmaceutical giants, startups, and investors. The forum’s unique capacity to unite these stakeholders accelerates the translation of fundamental aging research into viable therapeutics that extend healthy human lifespan. In 2025, the conference will pioneer novel initiatives, including a dedicated Longevity Medicine Day, aimed at clinicians and health practitioners focusing on evidence-based interventions for age-associated diseases.
The critical importance of ARDD is reflected in its ability to showcase pharmaceutical industry leaders such as Novartis, Biogen, Eli Lilly, and others who actively engage in aging research. Their presence at previous meetings solidifies ARDD as the central venue for unveiling next-generation therapeutics targeting aging mechanisms. The integration of cutting-edge AI applications in drug discovery further distinguishes ARDD, with industry experts exploring artificial intelligence as a pivotal tool in accelerating candidate drug identification, personalized treatment regimens, and clinical trial design.
Longevity research at ARDD highlights the shift from viewing aging solely as an inexorable decline to recognizing it as a malleable biological process amenable to intervention. This paradigm shift opens unprecedented avenues for drug development aimed at not only extending lifespan but more importantly enhancing healthspan. The inclusion of Longevity Medicine Day underscores the translation of benchside discoveries to bedside applications, offering clinicians insights on novel diagnostics, biomarkers, and therapeutic strategies to manage aging-related pathologies with scientific rigor.
Mitra Bio’s sponsorship symbolizes a confluence of research innovation and entrepreneurial vision. Their skin epigenetic testing platform exemplifies the intersection of omics technologies, bioinformatics, and clinical utility—a triad central to next-generation precision medicine approaches in aging. By enabling non-invasive monitoring of biological aging in easily accessible tissues such as skin, Mitra Bio paves the way for earlier intervention, personalized skincare, and improved patient care paradigms, reflecting a broader trend embracing digital aging biomarkers.
The integrative nature of ARDD and the participation of companies like Mitra Bio emphasize the dynamic expansion and maturation of the aging research community. The conference strives to bridge gaps between mechanistic biological insights, technological advancements, clinical translation, and commercial scalability. This holistic approach is essential to surmount challenges inherent in aging biology, including complexity, heterogeneity, and multifactorial etiologies.
In summary, ARDD 2025 promises to be a landmark event within the longevity research landscape. It will bring together Nobel Prize-winning scientists, industry thought leaders, innovative startups, and healthcare professionals under one roof to explore the frontiers of aging science and drug discovery. With a robust agenda featuring multidisciplinary scientific sessions, collaborative workshops, and industry showcases, ARDD stands as a beacon for advancing the future of healthy longevity medicine.
For media inquiries, further information, and interview requests related to ARDD 2025 or Mitra Bio, interested parties may contact ardd@pharma.ai or reach out directly to Mitra Bio media representative Jay Yeung at jay@mitrabio.tech. Additional information about Mitra Bio’s novel skin epigenetic testing approach can be found at mitrabio.tech and their LinkedIn profile.
Image Credits: Mitra Bio
Keywords: Health and medicine, aging research, drug discovery, longevity science, skin epigenetics, non-invasive testing, molecular biology, biotechnology, pharmaceutical industry, artificial intelligence, clinical interventions, precision medicine
